---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-314214"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2026-07-23T20:34:53+00:00"
generated_at: "2026-07-23T20:36:16.782868+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics enters $380M at-the-market equity distribution agreement with J.P. Morgan

## Summary
- Up to $380M of common stock may be sold through J.P. Morgan as sales agent.
- Sales agent commission up to 3.0% of gross sales price per share sold.
- Company not obligated to sell any shares; may suspend solicitations at any time.
- Sales may be made at market prices on Nasdaq or in block transactions.
- Prospectus supplement filed July 23, 2026; shares offered under existing S-3.

## SEC filing metadata
- accession: 0001193125-26-314214
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2026-07-23T20:34:53+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000119312526314214/0001193125-26-314214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000119312526314214/d143170d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-314214
- JSON: https://secwatch.observer/filing/0001193125-26-314214.json
- Plain text: https://secwatch.observer/filing/0001193125-26-314214.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.